Publication

Effect of a new synbiotic mixture on atopic dermatitis in infants: a randomized-controlled trial

Synbad Study Grp, van der Aa, L. B., Heymans, H. S., van Aalderen, W. M., Smitt, J. H. S., Knol, J., Ben Amor, K., Goossens, D. A. & Sprikkelman, A. B., May-2010, In : Clinical and Experimental Allergy. 40, 5, p. 795-804 10 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Effect of a new synbiotic mixture on atopic dermatitis in infants a randomized‐controlled trial

    Final publisher's version, 258 KB, PDF document

DOI

  • Synbad Study Grp
  • L. B. van der Aa
  • H. S. Heymans
  • W. M. van Aalderen
  • J. H. Sillevis Smitt
  • J. Knol
  • K. Ben Amor
  • D. A. Goossens
  • A. B. Sprikkelman

P>Background

Clinical trials investigating the therapeutic effect of probiotics on atopic dermatitis (AD) show inconsistent results. Better results can possibly be achieved by combining probiotics with prebiotics, i.e. synbiotics.

Objective

To investigate the therapeutic effect of a synbiotic mixture on the severity of AD in infants.

Methods

In a double-blind, placebo-controlled multi-centre trial, 90 infants with AD [SCORing Atopic Dermatitis (SCORAD) score >= 15], aged <7 months and exclusively formula fed, were randomly assigned to receive either an extensively hydrolysed formula with Bifidobacterium breve M-16V and a galacto-/fructooligosaccharide mixture (Immunofortis (R)), or the same formula without synbiotics for 12 weeks. The primary outcome was severity of AD, assessed using the SCORAD index. A secondary outcome measure was intestinal microbiota composition.

Results

There was no difference in SCORAD score improvement between the synbiotic and the placebo group. The synbiotic group did have a significantly higher percentage of bifidobacteria (54.7% vs. 30.1%, P <0.001) and significantly lower percentages of Clostridium lituseburense/Clostridium histolyticum (0.5 vs. 1.8, P=0.02) and Eubacterium rectale/Clostridium coccoides (7.5 vs. 38.1, P <0.001) after intervention than the placebo group. In the subgroup of infants with IgE-associated AD (n=48), SCORAD score improvement was significantly greater in the synbiotic than in the placebo group at week 12 (-18.1 vs. -13.5 points, P=0.04).

Conclusions

This synbiotic mixture does not have a beneficial effect on AD severity in infants, although it does successfully modulate their intestinal microbiota. Further randomized-controlled trials should explore a possible beneficial effect in IgE-associated AD.

Cite this as: L. B. van der Aa, H. S. Heymans, W. M. van Aalderen, J. H. Sillevis Smitt, J. Knol, K. Ben Amor, D. A. Goossens, A. B. Sprikkelman and the Synbad Study Group, Clinical & Experimental Allergy, 2010 (40) 795-804.

Original languageEnglish
Pages (from-to)795-804
Number of pages10
JournalClinical and Experimental Allergy
Volume40
Issue number5
Publication statusPublished - May-2010
Externally publishedYes

    Keywords

  • atopic dermatitis, infant, prebiotics, probiotics, synbiotics, PLACEBO-CONTROLLED TRIAL, IN-SITU HYBRIDIZATION, LACTIC-ACID BACTERIA, RNA-TARGETED PROBES, DOUBLE-BLIND, GALACTO-OLIGOSACCHARIDES, LACTOBACILLUS-RHAMNOSUS, OLIGONUCLEOTIDE PROBES, INTESTINAL MICROFLORA, PROBIOTIC BACTERIA

ID: 71334389